Open AccessRandomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
Author(s) -
Dmitriy Zamarin,
Robert A. Burger,
Michael W. Sill,
Daniel J. Powell,
Heather A. Lankes,
Michael D. Feldman,
Oliver Zivanovic,
Camille C. Gunderson,
Emily Ko,
Cara Mathews,
Sudarshan Sharma,
Andrea R. Hagemann,
Samir N. Khleif,
Carol Aghajanian
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.02059
Subject(s) - nivolumab , medicine , ipilimumab , hazard ratio , oncology , adverse effect , randomized controlled trial , confidence interval , cancer , immunotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom